新股消息 | 勤浩医药递表港交所 主要专注于开发肿瘤学领域的潜在同类最佳靶向疗法

Company Overview - Qinhau Pharmaceutical is a biopharmaceutical company focused on developing potential best-in-class targeted therapies in oncology, with a strong pipeline of innovative candidates centered around the RAS signaling pathway and synthetic lethality mechanisms [2] - The core product GH21 is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials, having received IND approval for monotherapy in advanced solid tumors from the National Medical Products Administration (NMPA) in November 2021 [2][3] - The company has a pipeline of seven self-developed candidates, including four in clinical stages, one approved by both NMPA and FDA, and two in preclinical stages [3] Clinical Trials and Pipeline - GH21 is undergoing several clinical trials, including a Phase 1b/2 trial in combination with Gossamer and Osimertinib, with IND approvals obtained in June 2024 and November 2023 respectively [3] - GH55, another candidate targeting the RAS signaling pathway, is in a Phase 1 trial for MAPK pathway-activated solid tumors, having received IND approval in September and November 2022 [5] - The company is also developing five candidates leveraging synthetic lethality, including GH56 and GH2616, both in Phase 1 trials, and GH31, which has received IND approval [5][6] Market Potential - The global oncology drug market is projected to grow from $167 billion in 2020 to $262 billion by 2024, with a CAGR of 11.9%, and expected to reach $646 billion by 2033 [10] - The synthetic lethality drug market is anticipated to expand from $2.2 billion in 2020 to $4.2 billion by 2024, with a CAGR of 17.8%, and further increase to $17.6 billion by 2033 [19] - The SHP2 inhibitor market is expected to emerge in 2027, with projections of growth from approximately $329 million in 2029 to about $4.8 billion by 2033, reflecting a CAGR of 95.6% [13] Financial Performance - Qinhau Pharmaceutical reported revenues of approximately 4.69 million RMB for the fiscal year 2024, 3.73 million RMB for the nine months ending September 30, 2024, and 0.981 million RMB for the nine months ending September 30, 2025 [8][9] - The company incurred losses of approximately 1.52 billion RMB for the fiscal year 2024, 965.06 million RMB for the nine months ending September 30, 2024, and 988.87 million RMB for the nine months ending September 30, 2025 [8][9]